Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionAlps Advisors Inc
Latest Disclosed Ownership2,268 shares
Latest Disclosed Value $ 1,012,753
Alps Advisors Inc reports 9.21% decrease in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 8, 2026 - Alps Advisors Inc filed a 13F-HR form disclosing ownership of 2,268 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $1,012,753 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 2,498 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -9.21% during the quarter. The current value of the position is $971,475 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-08 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,268 -230 -9.21 1,013 -10.60 0.0044
2026-02-12 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,498 99 4.13 1,132 20.55 0.0066
2025-11-05 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,399 1,160 93.62 940 70.42 0.0052
2025-08-11 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,239 -78 -5.92 552 -13.64 0.0032
2025-04-30 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,317 529 67.13 639 101.26 0.0037
2025-02-13 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 788 -17 -2.11 317 -15.24 0.0020
2024-11-12 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 805 -1,327 -62.24 374 -62.56 0.0025
2024-08-13 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,132 80 3.90 999 16.57 0.0069
2024-05-14 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,052 -291 -12.42 858 -10.07 0.0061
2024-02-14 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,343 -311 -11.72 953 3.36 0.0075
2023-11-14 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,654 183 7.41 923 6.10 0.0077
2023-08-14 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,471 839 51.41 870 69.07 0.0076
2023-05-10 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,632 -995 -37.88 514 -32.19 0.0045
2023-02-14 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,627 -120 -4.37 759 -4.65 0.0068
2022-11-14 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,747 411 17.59 795 20.82 0.0075
2022-08-15 2022-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 2,336 97 4.33 658 12.67 0.0064
2022-08-11 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,336 97 658 0.0063
2022-05-16 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,239 -792 -26.13 584 -12.31 0.0063
2022-02-09 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,031 -354 -10.46 666 8.47 0.0075
2021-11-15 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,385 1,614 91.13 614 71.99 0.0059
2021-08-11 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,771 -63 -3.44 357 -9.39 0.0032
2021-05-07 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,834 -1,432 -43.85 394 -48.96 0.0038
2021-02-03 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,266 -272 -7.69 772 -19.83 0.0087
2020-11-05 2020-09-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 3,538 1,323 59.73 963 49.77 0.0142
2020-11-04 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,538 1,323 963 12,341.9987
2020-08-05 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,215 1,149 107.79 643 153.15 0.0086
2020-05-06 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,066 -921 -46.35 254 -41.61 0.0039
2020-02-07 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,987 -87 -4.19 435 23.93 0.0034
2019-11-04 2019-09-30 13F VERTEX PHARM COMMON STOCK 92532F100 2,074 -21 -1.00 351 -8.59 0.0027
2019-08-07 2019-06-30 13F VERTEX PHARM COMMON STOCK 92532F100 2,095 -112 -5.07 384 -5.42 0.0028
2019-05-01 2019-03-31 13F VERTEX PHARM COMMON STOCK 92532F100 2,207 2,207 406 0.0029
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.